CN115932265B - 预测cd19抗体治疗在患者中的治疗益处的方法 - Google Patents

预测cd19抗体治疗在患者中的治疗益处的方法

Info

Publication number
CN115932265B
CN115932265B CN202211271570.5A CN202211271570A CN115932265B CN 115932265 B CN115932265 B CN 115932265B CN 202211271570 A CN202211271570 A CN 202211271570A CN 115932265 B CN115932265 B CN 115932265B
Authority
CN
China
Prior art keywords
cells
peripheral
baseline
cell
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202211271570.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN115932265A (zh
Inventor
J·恩德尔
M·温德尔里奇
R·博克斯哈默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Morphosys GmbH
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys GmbH, Incyte Corp filed Critical Morphosys GmbH
Publication of CN115932265A publication Critical patent/CN115932265A/zh
Application granted granted Critical
Publication of CN115932265B publication Critical patent/CN115932265B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202211271570.5A 2016-05-30 2017-05-30 预测cd19抗体治疗在患者中的治疗益处的方法 Active CN115932265B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16171885 2016-05-30
EP16171885.3 2016-05-30
CN201780033793.9A CN109313194B (zh) 2016-05-30 2017-05-30 预测cd19抗体治疗在患者中的治疗益处的方法
PCT/EP2017/063045 WO2017207574A1 (en) 2016-05-30 2017-05-30 Methods for predicting therapeutic benefit of anti-cd19 therapy in patients

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780033793.9A Division CN109313194B (zh) 2016-05-30 2017-05-30 预测cd19抗体治疗在患者中的治疗益处的方法

Publications (2)

Publication Number Publication Date
CN115932265A CN115932265A (zh) 2023-04-07
CN115932265B true CN115932265B (zh) 2026-04-14

Family

ID=56116221

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211271570.5A Active CN115932265B (zh) 2016-05-30 2017-05-30 预测cd19抗体治疗在患者中的治疗益处的方法
CN201780033793.9A Active CN109313194B (zh) 2016-05-30 2017-05-30 预测cd19抗体治疗在患者中的治疗益处的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780033793.9A Active CN109313194B (zh) 2016-05-30 2017-05-30 预测cd19抗体治疗在患者中的治疗益处的方法

Country Status (26)

Country Link
US (2) US20190195879A1 (enExample)
EP (2) EP3465214B1 (enExample)
JP (2) JP7066639B2 (enExample)
KR (1) KR102416144B1 (enExample)
CN (2) CN115932265B (enExample)
AU (1) AU2017272608B2 (enExample)
CY (1) CY1124768T1 (enExample)
DK (2) DK3465214T3 (enExample)
EA (1) EA201892542A1 (enExample)
ES (2) ES2981046T3 (enExample)
FI (1) FI3916392T3 (enExample)
HR (2) HRP20210938T1 (enExample)
HU (2) HUE054860T2 (enExample)
IL (1) IL263103B2 (enExample)
LT (2) LT3465214T (enExample)
MA (2) MA45124B1 (enExample)
MD (2) MD3465214T2 (enExample)
MX (2) MX388502B (enExample)
PL (2) PL3465214T3 (enExample)
PT (2) PT3465214T (enExample)
RS (2) RS62155B1 (enExample)
SG (2) SG10201911958SA (enExample)
SI (2) SI3916392T1 (enExample)
SM (2) SMT202100291T1 (enExample)
WO (1) WO2017207574A1 (enExample)
ZA (2) ZA201808647B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
SMT202100317T1 (it) 2016-06-27 2021-07-12 Morphosys Ag Formulazioni di anticorpi anti-cd19
WO2018078123A1 (en) 2016-10-28 2018-05-03 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
CN114072424A (zh) 2019-05-03 2022-02-18 莫佛塞斯公司 具有有限数量的nk细胞的患者中的抗cd19疗法
WO2021084062A1 (en) * 2019-10-31 2021-05-06 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
TW202131950A (zh) * 2019-10-31 2021-09-01 德商莫菲西斯公司 依序抗ｃｄ１９療法
EP4168449A1 (en) * 2020-06-22 2023-04-26 MorphoSys AG Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint
AU2021391623A1 (en) * 2020-12-04 2023-06-29 Incyte Corporation Anti-cd19 combination therapy
WO2026024668A1 (en) * 2024-07-22 2026-01-29 Abbott Laboratories Method of determining a volume of a liquid in a sample

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103703027A (zh) * 2011-08-16 2014-04-02 莫佛塞斯公司 使用抗cd-19抗体和嘌呤类似物的联合治疗
WO2015195498A1 (en) * 2014-06-16 2015-12-23 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
PT1974747E (pt) * 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
JP4361273B2 (ja) 2001-02-27 2009-11-11 アメリカ合衆国 潜在的な血管形成阻害剤としてのサリドマイド類似体
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
PT1853718E (pt) * 2005-02-15 2015-11-12 Univ Duke Anticorpos anti-cd19 e usos em oncologia
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
RS53263B (sr) 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US20100167315A1 (en) 2006-09-13 2010-07-01 Glycode Method for investigating the response to a treatment with a monoclonal antibody
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
SG190254A1 (en) 2010-11-15 2013-06-28 Medimmune Llc Combination therapy for b cell lymphomas
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
SG10201606785UA (en) 2011-08-16 2016-10-28 Morphosys Ag Combination therapy with an anti - cd19 antibody and a nitrogen mustard
EP2791165A4 (en) * 2011-12-12 2015-08-05 Pikamab Inc PREDICTING SENSITIVITY TO ANTIBODY MAINTENANCE THERAPY
US20130273032A1 (en) 2012-03-02 2013-10-17 Roche Glycart Ag Predictive biomarker for cancer treatment with adcc-enhanced antibodies
CA2935748A1 (en) * 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US10969391B2 (en) 2014-07-11 2021-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing hematological cancers
JP6916741B2 (ja) 2015-05-26 2021-08-11 モルフォシス・アーゲー 抗ｃｄ１９抗体およびブルトン型チロシンキナーゼ阻害剤の組み合わせ、およびその使用
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
SMT202100317T1 (it) 2016-06-27 2021-07-12 Morphosys Ag Formulazioni di anticorpi anti-cd19
WO2018078123A1 (en) 2016-10-28 2018-05-03 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
HUE063119T2 (hu) 2017-05-31 2024-01-28 Morphosys Ag Kezelési paradigma anti-CD19 antitest és venetoclax kombinációs kezeléshez
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
CN114072424A (zh) 2019-05-03 2022-02-18 莫佛塞斯公司 具有有限数量的nk细胞的患者中的抗cd19疗法
LT4051710T (lt) 2019-10-31 2026-03-10 Incyte Corporation Priešnavikinė kompleksinė terapija, apimanti anti-cd19 antikūną ir gama delta ląsteles
TW202131950A (zh) 2019-10-31 2021-09-01 德商莫菲西斯公司 依序抗ｃｄ１９療法
WO2021084062A1 (en) 2019-10-31 2021-05-06 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
EP4168449A1 (en) 2020-06-22 2023-04-26 MorphoSys AG Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint
AU2021391623A1 (en) 2020-12-04 2023-06-29 Incyte Corporation Anti-cd19 combination therapy
US20230357392A1 (en) 2021-12-22 2023-11-09 Morphosys Ag Treatment Paradigm for an Anti-CD19 Antibody Therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103703027A (zh) * 2011-08-16 2014-04-02 莫佛塞斯公司 使用抗cd-19抗体和嘌呤类似物的联合治疗
WO2015195498A1 (en) * 2014-06-16 2015-12-23 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)

Also Published As

Publication number Publication date
LT3465214T (lt) 2021-10-11
EP3916392A1 (en) 2021-12-01
US20220283166A1 (en) 2022-09-08
WO2017207574A1 (en) 2017-12-07
CY1124768T1 (el) 2022-11-25
CN109313194A (zh) 2019-02-05
DK3465214T3 (da) 2021-05-31
EA201892542A1 (ru) 2019-06-28
ES2878156T3 (es) 2021-11-18
CA3025823A1 (en) 2017-12-07
ES2981046T3 (es) 2024-10-07
KR20190013980A (ko) 2019-02-11
SI3465214T1 (sl) 2021-12-31
MX388502B (es) 2025-03-20
HUE067450T2 (hu) 2024-10-28
MA45124B1 (fr) 2021-05-31
DK3916392T3 (da) 2024-05-21
MA57021B1 (fr) 2024-05-31
KR102416144B1 (ko) 2022-07-04
FI3916392T3 (fi) 2024-06-03
JP7511806B2 (ja) 2024-07-08
LT3916392T (lt) 2024-08-26
RS62155B1 (sr) 2021-08-31
AU2017272608A1 (en) 2018-12-06
EP3916392B1 (en) 2024-05-01
JP7066639B2 (ja) 2022-05-13
MD3916392T2 (ro) 2024-10-31
MA45124A (fr) 2017-12-07
IL263103B1 (en) 2023-06-01
BR112018074603A2 (pt) 2019-03-19
ZA202100296B (en) 2025-05-28
PT3465214T (pt) 2021-06-30
EP3465214A1 (en) 2019-04-10
HRP20210938T1 (hr) 2021-09-03
US12631639B2 (en) 2026-05-19
SMT202100291T1 (it) 2021-07-12
IL263103B2 (en) 2023-10-01
ZA201808647B (en) 2021-05-26
JP2022119764A (ja) 2022-08-17
PT3916392T (pt) 2024-06-04
SG11201810159TA (en) 2018-12-28
HRP20240670T1 (hr) 2024-09-27
AU2017272608B2 (en) 2023-08-10
CN109313194B (zh) 2022-11-04
PL3916392T3 (pl) 2024-09-23
HUE054860T2 (hu) 2021-10-28
EP3465214B1 (en) 2021-04-28
MD3465214T2 (ro) 2021-09-30
SG10201911958SA (en) 2020-02-27
MX2018014702A (es) 2019-10-02
US20190195879A1 (en) 2019-06-27
NZ748468A (en) 2025-05-30
SMT202400204T1 (it) 2024-09-16
RS65540B1 (sr) 2024-06-28
MX2021014963A (es) 2022-02-24
PL3465214T3 (pl) 2021-12-20
JP2019519770A (ja) 2019-07-11
IL263103A (en) 2018-12-31
SI3916392T1 (sl) 2024-10-30
CN115932265A (zh) 2023-04-07

Similar Documents

Publication Publication Date Title
US12631639B2 (en) Methods for predicting therapeutic benefit of anti-CD19 therapy in patients
JP2023112043A (ja) 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
US20220242952A1 (en) Anti-cd19 therapy in patients having a limited number of nk cells
JP2011515497A (ja) 骨髄性血液学的増殖性疾患と関連する免疫グロブリンおよび／またはＴｏｌｌ様受容体タンパク質ならびにその使用
HK40065007A (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
HK40065007B (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
HK40002753A (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
HK40002753B (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
EA040320B1 (ru) Способы прогнозирования у пациентов терапевтического эффекта терапии с использованием антител к cd19
NZ788788A (en) Methods for predicting therapeutic benefit of anti-CD19 therapy in patients
BR112018074603B1 (pt) Método para identificar um sujeito tendo leucemia linfocítica crónica, e anticorpo anti-cd19

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20250316

Address after: Delaware, USA

Applicant after: INCYTE Corp.

Country or region after: U.S.A.

Address before: Praneger, Germany

Applicant before: MORPHOSYS AG

Country or region before: Germany

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant